Photo credit: aqsaqal.com
More than 600 mechanical ventilation devices have been delivered to other countries by Russia, TASS reports. This was told by the head of the Ministry of Industry and Trade Denis Manturov during a speech in the upper house of the Russian parliament. Batches of medical equipment have already been sent to Belarus, Serbia, Italy, Uzbekistan.
According to the head of the department, a contract has been signed to sell temperature measuring terminals to the United States. He noted that previously the companies had provided a stock of antivirus products to Russia.
The country has also received many applications for Avifavir. Manturov noted that many countries were interested in this medicine. Requests are made by European, Latin American countries, the CIS countries and Southeast Asia.
Russkiy Mir
reported that clinical trials of Avifavir were successful. The drug has proven to be highly effective in the treatment of patients with COVID-19. According to studies, the elimination of the virus from the patient's body requires an average of about four days. In the control group, this process required twice as much time.
Previously, Japanese scientists created Favipiravir to treat diseases caused by RNA viruses. When the epidemic of coronavirus infection began, it was used by Chinese and Japanese doctors. At the same time, the patent, which gave a monopoly on the release of the drug, ended in 2019. Many pharmaceutical companies have begun working on a copy of this medicine. The pandemic particularly spurred work.
The ChemRar company supported by the Russian Direct Investment Fund (RDIF) was the first to produce the drug in Russia. This medicine has the same active substance as Favipiravir.
According to Kirill Dmitriev, head of the RDIF, Avifavir could be the most promising anti-COVID-19 drug in the world. He recalled that Avifavir was the first registered drug based on Favipiravir.
Russkiy Mir
